[Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice].

The aim of this work is to provide an updated overview of the use of sotorasib in advanced NSCLC harboring KRAS G12C mutations, summarizing both clinical trial and real-world evidence supporting its use in pretreated patients. The analysis focuses on efficacy, safety, and management of key toxicities, with particular attention to hepatic adverse events. Specific emphasis is also placed on intracranial activity and the use of sotorasib in special subgroups, including frail patients and those with comorbidities, providing a practical framework for daily clinical practice. The objective is to offer evidence-based guidance to facilitate treatment personalization and improve clinical outcomes in this complex patient population.